Introduction {#s001}
============

A [significant antioxidant]{.smallcaps} role in pancreatic β-cells ([@B1], [@B2], [@B9], [@B13], [@B23], [@B28], [@B29], [@B31], [@B42], [@B45], [@B48], [@B54]) or α-cells ([@B3]) is provided by mitochondrial uncoupling protein-2 (UCP2). This was evidenced for UCP2 KO mice of three highly congenic strain backgrounds, all of which exhibit oxidative stress (decreased ratios of reduced-to-oxidized glutathione in blood or tissues), elevated levels of antioxidant enzymes, and increased nitrotyrosine content in their islets ([@B42]). Pancreatic β-cells from UCP2 KO mice showed chronically higher reactive oxygen species (ROS) when compared with wild-type mice ([@B29]). Mice with selective knockout of UCP2 in pancreatic β-cells exhibited increased glucose-induced inner mitochondrial membrane (IMM) potential (ΔΨ~m~) and elevated intracellular ROS ([@B48]).

Fatty acid (FA)--stimulated and redox-stimulated insulin releases have not been fully understood as well as acute lipotoxicity, instantly decreasing insulin secretion in pancreatic β-cells. We describe a feedback antioxidant mechanism based on redox signaling initiated by FA β-oxidation, and promoted plus amplified by mitochondrial phospholipase iPLA~2~γ. Not only the antioxidant synergy of iPLA~2~γ with mitochondrial UCP2 is demonstrated, but also the iPLA~2~γ role in the amplifying mechanism, since further free FAs cleaved by iPLA~2~γ serve as "messengers" for G-protein--coupled receptor 40 (GPR40). Consequently, the iPLA~2~γ/UCP2 synergy regulates glucose-stimulated, redox-, and FA-stimulated insulin release in pancreatic β-cells.

Superoxide formation is an inevitable side reaction at Complex I and III of mitochondrial respiratory chain ([@B24]) and in 2-oxoacid dehydrogenases ([@B41], [@B46]). Mitochondrial superoxide formation increases with an increasing substrate (NADH) load, represented by increasing glucose in pancreatic β-cells ([@B10]). Similarly, in numerous situations of local or global electron transfer retardation within the respiratory chain, superoxide production is specifically elevated. This serves for redox signaling, for example, during initiation of hypoxic gene expression remodeling ([@B27]).

Mitochondrial H^+^ pumping is usually tightly coupled to the H^+^ backflow *via* the ATP synthase. Since any uncoupling of this accelerates electron transfer within the respiratory chain (and hence respiration), the superoxide formation is attenuated by mitochondrial uncoupling. This represents the key mechanism exerted by UCP2, although it slightly attenuates ATP synthesis. In pancreatic β-cells, the increase in oxidative phosphorylation (OXPHOS) substantiates the canonical mechanism of glucose sensing. The increasing ATP/ADP ratio at higher glucose initiates the glucose-stimulated insulin secretion (GSIS) ([@B5], [@B26], [@B47]).

By shifting ROS homeostasis, UCP2 may participate in redox signaling in β-cells ([@B31], [@B48]), which may be easily transmitted due to the low capacity of redox buffers ([@B23]). H~2~O~2~-responsive gene expression is manifested for both major differentiation factors of β-cells, PDX-1 and MafA ([@B47]). Impaired antioxidant defense leading to chronic oxidative stress may affect insulin secretion machinery that is finely tuned for optimum GSIS in β-cells, as recognized in type 2 diabetes patients ([@B16], [@B39], [@B40]) and rodent diabetic models ([@B30], [@B33]). ROS may further accelerate diabetic development by promoting apoptosis, thus decreasing β-cell mass ([@B51]). Consequently, oxidative stress serves as a mediator of β-cell remission.

The function of UCP1 ([@B12]) and recombinant UCP2 ([@B6], [@B7], [@B20], [@B53]) is essentially dependent on its anionic transport substrates, nonesterified fatty acids (FAs) ([@B6], [@B7], [@B18], [@B20], [@B53]). However, FAs augment GSIS in β-cells, when exposed for hours ([@B8], [@B15], [@B19]), but chronically excessive saturated FAs suppress insulin secretion ([@B32], [@B43], [@B52]), the phenomenon termed lipotoxicity ([@B15], [@B19]). As a simplifying scheme, UCP2 might counteract acute lipotoxicity arising from oxidative stress due to the incoming FAs. Nevertheless, its role should be further clarified.

The role of phospholipases A~2~ (PLA~2~) ([@B21], [@B22], [@B25], [@B34], [@B35], [@B38]) residing in (such as iPLA~2~β) ([@B34]) or recruited to mitochondria of pancreatic β-cells should also be explained in relation to their activation. PLA~2~ may amplify lipotoxicity, but in concert with UCP2 a hypothetical synergic antioxidant activity may prevail, such as with mitochondrial iPLA~2~γ in heart ([@B25]) and lung tissues ([@B21]). Both iPLA~2~γ and iPLA~2~β belong to the group VI of PLA~2~s ([@B38]) ascribed to the cytosolic Ca^2+^-[i]{.ul}ndependent [i]{.ul}PLA~2~s. They are also termed patatin-like phospholipase domain-containing lipases (PNPLAs), which, besides the release of unsaturated FAs by cleaving the *sn*-2 ester bond of membrane phospholipids, also cleave saturated FAs at the *sn*-1 ester bond ([@B21], [@B38]). The β-isoform is sensitive to a stereo-selective inhibitor [s]{.smallcaps}-bromoenol lactone ([s]{.smallcaps}-BEL), whereas the γ-isoform (PNPLA8) is sensitive to [r]{.smallcaps}-BEL ([@B22]). Alternative splice isoforms of iPLA~2~γ 88-, 77-, 74-, and 63-kDa potentially exist, with the 63-kDa being peroxisomal ([@B35]).

The FAs were also implicated in the insulin release in pancreatic β-cells. Although the mechanism is not decisively elucidated ([@B15]), the G-protein--coupled receptor 40 (GPR40) has been recently implicated in insulin-stimulating responses ([@B11]). In addition, the threshold FA concentration, above which acute lipotoxicity is exerted and below which insulin release is stimulated, is not known.

In this work, we aimed at studying how UCP2-mediated antioxidant action may be initiated and regulated and at elucidating its functional relationship with PLA~2~s. We revealed the antioxidant synergy of UCP and iPLA~2~γ and describe in detail its impact on acute lipotoxicity and insulin secretion in model pancreatic β-cells, insulinoma INS-1E cells.

Results {#s002}
=======

Uncoupling manifested by respiration increase after *tert*-butylhydroperoxide addition to INS-1E cells is absent in cells silenced for UCP2 or iPLA~2~γ {#s003}
-------------------------------------------------------------------------------------------------------------------------------------------------------

Nontransfected INS-1E cells with glucose lowered to 3 m*M* still exhibited a substantial respiration of 23.6±6.3 pmol O~2~·s^−1^×10^−6^ cells (*n*=49; number of preparations *N*=10). The corresponding state may be regarded as the phosphorylating state-3, although with low substrate levels available for OXPHOS. *Tert*-butylhydroperoxide (TBHP) addition resulted in the acceleration of respiration, so that the differences (Δ~TBHP~J~O2~) between respiration rates before (J^0^~O2~) and after TBHP exhibited a saturating dependence on glucose.

INS-1E cells transfected with nontargeting microRNA (miRNA) (ntgINS-1E cells) and with glucose lowered to 3 m*M* exhibited virtually unchanged respiration of J^0^~O2~=25.3±6.3 pmol O~2~·s^−1^×10^−6^cells (*n*=356; *N*=51) and responded to TBHP in the same way ([Fig. 1A](#f1){ref-type="fig"}). UCP2-silenced cells ([Supplementary Fig. S1A, C](#SD1){ref-type="supplementary-material"}; Supplementary Data are available online at [www.liebertpub.com/ars](www.liebertpub.com/ars)) with glucose lowered to 3 m*M* did not change respiration (J^0^~O2~=24.2±7.4 pmol O~2~·s^−1^×10^−6^ cells; *n*=358; *N*=58). However, they responded much less to TBHP addition with increasing glucose ([Fig. 1A](#f1){ref-type="fig"}). The residual response predominantly reflects contribution of the ADP/ATP carrier ([@B25]), since it was prevented by bongkrekic acid, which blocked the whole response in UCP2-silenced cells ([Fig. 1A](#f1){ref-type="fig"}).

![***Tert*-butylhydroperoxide (TBHP)-induced respiratory elevation and IMM potential decrease in INS-1E cells.** ntgINS-1E cells: *black circles* or *bars*; UCP2-silenced cells: *dark red squares* or *bars*; iPLA~2~γ-silenced cells: *green diamonds* or *bars*; iPLA~2~β-silenced cells: *yellow bars* **(I)**. ANOVA \**p*\<0.05; \*\**p*\<0.01; \*\*\**p*\<0.001. **(A, B)** Glucose-dependent respiration elevations: Glucose addition to INS-1E cells respiring at state-3 was performed after cell preincubation in a culture medium with 3 m*M* glucose for 16 h. Subsequently, 250 μ*M* TBHP was added to cells assayed in this medium. The resulting respiration elevation responses Δ~TBHP~J~O2~ are plotted *versus* final glucose concentration (*n*=3--7 estimations for each concentration, 8--12 for 25 m*M* glucose). *Red*-edge symbols: 100 μ*M* bongkrekic acid was present during the assay. **(C, D)** Glucose-dependent ΔΨ~m~ decrease: TBHP-induced decreases in ΔΨ~m~, δ~TBHP~ΔΨ~m~, were assayed as TMRE fluorescence increase (F~TBHP~--F~0~)/F~0~ between the initial (F~0~) and fluorescence after TBHP addition (F~TBHP~) in relative units (*n*=3). Uncoupling of mitochondria by 2.5 μ*M* FCCP prevented δ~TBHP~ΔΨ~m~ decreases, which then reached values \<1 (data not shown). This also confirms that plasma membrane potential did not affect the assay. **(E--I)** [r]{.smallcaps}-BEL *versus* [s]{.smallcaps}-BEL inhibition of TBHP-induced uncoupling assayed as respiration elevations Δ~TBHP~ J~O2~ **(E, F, I)**; or ΔΨ~m~ decreases **(G, H)**. The effects of 40 μ*M* [r]{.smallcaps}-BEL ("[r]{.smallcaps}BEL") and 40 μ*M* [s]{.smallcaps}-BEL ("[s]{.smallcaps}BEL") were quantified for cells remaining at 3 m*M* glucose **(**"Glc 3" in **E, F, I)** and cells subjected to 25 m*M* glucose **(**"25" in **E, F, I)** (*n*=3, 11 for ntg controls and UCP2-silenced cells). **(J)** Effect of antioxidants on TBHP-induced uncoupling of INS-1E cell respiration: The assay with 25 m*M* glucose was conducted as in **(A)** and with antioxidants: 0.5 μ*M* SkQ1 ("SkQ"); 2 m*M* N-acetyl-[l]{.smallcaps}-cysteine ("NAC"); 7.5 μ*M* ebselen; 200 μ*M* Trolox; and 100 μ*M* MnTBAP. "Catalase" represents catalase overexpression. It should be noted that MnTBAP in the presence of TBHP increased oxygen consumption even in the absence of cells, indicating that the observed effects of MnTBAP are not caused by interacting with cells or mitochondria, but by the formation of butylperoxy radicals, initiating peroxidation of the porphyrin organic groups at the expense of oxygen. ANOVA, analysis of variance; FCCP, trifluoromethoxy carbonylcyanide phenylhydrazone; IMM, inner mitochondrial membrane; MnTBAP, Mn(III)tetrakis(4-benzoic acid)porphyrin; [s]{.smallcaps}-BEL, [s]{.smallcaps}-bromoenol lactone; TMRE, tetramethylrhodamine ethyl ester; UCP2, uncoupling protein-2.](fig-1){#f1}

In addition, iPLA~2~γ-silenced cells ([Supplementary Fig. S1B, C](#SD1){ref-type="supplementary-material"}) with glucose lowered to 3 m*M* did not significantly change respiration (J^0^~O2~=19.4±3.9 pmol O~2~·s^−1^×10^−6^ cells; *n*=116; *N*=23; compared with own ntg shRNA controls having J^0^~O2~=22.4±3.3 pmol O~2~·s^−1^×10^−6^ cells; *n*=117; *N*=24). They also exhibited suppressed respiratory responses to TBHP addition with increasing glucose and complete inhibition by bongkrekic acid ([Fig. 1B](#f1){ref-type="fig"}).

To verify that the observed respiratory elevations represent a mild mitochondrial uncoupling, we monitored the IMM potential decrease (δ~TBHP~ΔΨ~m~) at various glucose concentrations, after TBHP addition to UCP2- ([Fig. 1C](#f1){ref-type="fig"}) and iPLA~2~γ-silenced INS-1E cells ([Fig. 1D](#f1){ref-type="fig"}). We found the same pattern as for respiration increases. Since the accelerated respiration, together with simultaneous ΔΨ~m~ decline, strictly defines mitochondrial uncoupling, we conclude that TBHP induces uncoupling in INS-1E cells in a UCP2- and iPLA~2~γ-dependent manner.

The iPLA~2~γ contribution also stems from the sensitivity to its stereo-selective inhibitor [r]{.smallcaps}-BEL, which prevented both TBHP-induced J~O2~ elevations ([Fig. 1E, F](#f1){ref-type="fig"} and [Supplementary Fig. S2A](#SD2){ref-type="supplementary-material"}) and ΔΨ~m~ drops ([Fig. 1G, H](#f1){ref-type="fig"}), whereas both were unaffected by [s]{.smallcaps}-BEL ([Fig. 1E--H](#f1){ref-type="fig"}). In contrast, cells silenced for iPLA~2~β responded to TBHP normally and this was not inhibited by [s]{.smallcaps}-BEL, the stereo-selective inhibitor of iPLA~2~β ([Fig. 1I](#f1){ref-type="fig"}). Similar UCP2- ([Supplementary Fig. S2B](#SD2){ref-type="supplementary-material"}) and iPLA~2~γ-dependent uncoupling (not shown) was induced by TBHP at state-4 set by oligomycin. We have also confirmed that the state-3 respiration of mitochondria isolated from INS-1E cells can be uncoupled in a UCP2-dependent manner ([Supplementary Fig. S3](#SD3){ref-type="supplementary-material"}).

TBHP-induced uncoupling is prevented by antioxidants {#s004}
----------------------------------------------------

As expected, UCP2-dependent TBHP-induced mitochondrial uncoupling in ntgINS-1E cells at 25 m*M* glucose was completely prevented by matrix-targeted antioxidant SkQ1 and substantially blocked by catalase overexpression ([Fig. 1J](#f1){ref-type="fig"}). Among nonmitochondrial antioxidants, only *N*-acetyl-[l]{.smallcaps}-cysteine and ebselen exhibited moderate prevention. Trolox, an alkyl-peroxyl free radical scavenger, had no effect ([Fig. 1J](#f1){ref-type="fig"}), excluding involvement of lipoperoxidation. A superoxide dismutase (SOD) mimetic, Mn(III)tetrakis(4-benzoic acid)porphyrin (MnTBAP), by direct interaction with TBHP, accelerated TBHP-induced respiration independently of UCP2 presence ([Fig. 1J](#f1){ref-type="fig"}).

iPLA~2~γ is directly activated by TBHP or H~2~O~2~ {#s005}
--------------------------------------------------

Reconstituted recombinant iPLA~2~γ was reversibly activated by H~2~O~2~ ([Fig. 2A--E](#f2){ref-type="fig"}) with a half-maximum activation constant AC~50~ corresponding to ∼1.5 nmol H~2~O~2~ per nmol of enzyme ([Fig. 2E](#f2){ref-type="fig"}). The H~2~O~2~-induced FA release in proteoliposomes containing iPLA~2~γ was fully reversed by membrane-permeable dithiothreitol (DTT) and partially by membrane-impermeable glutathione ([Fig. 2D, E](#f2){ref-type="fig"}). These results indicate that iPLA~2~γ activation by H~2~O~2~ is dependent on reversible oxidation of accessible cysteine residues. In cells, AC~50~ was 200 μ*M* for TBHP ([Supplementary Fig. S2A](#SD2){ref-type="supplementary-material"}).

![**Redox-dependent free FA release in proteoliposomes with recombinant iPLA~2~γ (A--E) and in INS-1E cells (F, G). (A, B, D, E)** Fluorimetrically indicated free FA release: Passive diffusion (flip) of FAs into the liposome interior was monitored by sulfopropylquinolinium fluorescence, which increases due to intraliposomal acidification concomitant to FA release. The fluorescence increase was induced by 25 μ*M* H~2~O~2~ (" +H~2~O~2~") in **(A, C, D)** and was absent without H~2~O~2~ **(**"no H~2~O~2~" in **A)**. Inhibition by 1 μ*M* [r]{.smallcaps}-BEL **(**" +H~2~O~2~+RBEL" in **A**), 10 m*M* glutathione **(**"GSH" in **D, E),** or 10 m*M* dithiothreitol **(**"DTT" in **D, E)** is also shown. **(B)** Without iPLA~2~γ ("no iPLA~2~γ"), H~2~O~2~ caused no intraliposomal acidification (" +H~2~O~2~") and the response was identical to the baseline ("no H~2~O~2~") in contrast to two additions of 10 μ*M* linoleic acid ("LA"), causing the instant intraliposomal acidification. Five micromolar bovine serum albumin ("BSA"), removing FAs, led to subsequent alkalization back toward the initial pH values. Proteoliposomes contained 0.04 μg of purchased **(A, C)** or 0.4 μg of the affinity-purified **(D, E)** recombinant human iPLA~2~γ per mg of phospholipids. **(E**) The H~2~O~2~ dose response for redox-stimulated FA-induced acidification rate is shown, yielding AC~50~ of 0.2 μ*M* H~2~O~2~, corresponding to 1.4 nmol H~2~O~2~ per nmol iPLA~2~γ. **(C, F, G)** GC/MS quantification of free FAs cleaved during 60 min at 30°C as induced by 25 μ*M* H~2~O~2~ ("H~2~O~2~") in iPLA~2~γ--proteoliposomes **(C)** with 0.04 μg of the purchased protein (Novus); or free FAs cleaved during 2 min at 37°C in INS-1E cells, ntg or silenced as ascribed **(F, G)**, supplied with 25 m*M* glucose, as induced by 250 μ*M* TBHP **(F)** or 75 nmol PA·l0^−6^ cells, corresponding to 0.2 pmol free PA **(G)**. Indicated FAs were detected in the absence of H~2~O~2~ or TBHP ("no add."), the presence of 25 μ*M* H~2~O~2~ ("H~2~O~2~"), 250 μ*M* TBHP ("TBHP"), or 150 μ*M* PA with 5% BSA; or additional 1 μ*M* **(C)** or 40 μ*M* **(F, G)** [r]{.smallcaps}-BEL (" +[r]{.smallcaps}-BEL"). Averages±s.d. of 3--7 **(G)** or 4--17 estimations are shown, recalculated relatively to the estimated total content of FA side chains **(C)** or the initial FA content **(F, G)**. ANOVA: \**p*\<0.1; \*\**p*\<0.05; \*\*\**p*\<0.001. FA, fatty acid; GC/MS, gas chromatography/mass spectrometry; PA, palmitic acid.](fig-2){#f2}

Gas chromatography/mass spectrometry quantification of released FAs from iPLA~2~γ-containing proteoliposomes after 60 min at 30°C had indicated a release of approximately 1 nmol^−1^·min·(mg protein)^−1^ (1.5% of phospholipid FAs) of free palmitic acid (PA), oleic, or linoleic acid, which was enhanced by H~2~O~2~, but not with [r]{.smallcaps}-BEL ([Fig. 2C](#f2){ref-type="fig"}). GC/MS analysis of TBHP- or PA-induced (*vide infra*) FA release in ntgINS-1E cells 2 min after the addition of 25 m*M* glucose is summarized in [Figure 2F and G](#f2){ref-type="fig"}. A substantial increase in free FAs occurred only on iPLA~2~γ activation by 250 μ*M* TBHP or 75 nmol PA·l0^−6^ cells, corresponding to 0.2 pmol free PA (other FAs increased, [Fig. 2G](#f2){ref-type="fig"}) and was blocked by 40 μ*M* [r]{.smallcaps}-BEL ([Fig. 2F, G](#f2){ref-type="fig"}). Along with unsaturated FAs, palmitic ([Fig. 2F](#f2){ref-type="fig"}) and stearic acid ([Fig. 2F, G](#f2){ref-type="fig"}) also were cleaved, which is characteristic of PNPLA subfamily of phospholipases ([@B38]). Consequently, we can conclude that H~2~O~2~- (*ex vivo* TBHP-) activated or PA-induced (*vide infra*) iPLA~2~γ cleaves FAs off mitochondrial phospholipids and provides them to UCP2 as the transport substrates, ensuring slight uncoupling of mitochondria.

Decrease of superoxide release into mitochondrial matrix on TBHP addition is absent in INS-1E cells silenced for UCP2 or iPLA~2~γ {#s006}
---------------------------------------------------------------------------------------------------------------------------------

We further investigated whether the observed TBHP-induced uncoupling attenuates mitochondrial superoxide production. We employed MitoSOX Red fluorescence ([@B10]), measuring the *in situ* surplus superoxide release into the mitochondrial matrix as the rate J~m~ of fluorescence changes in regions of interests identical to the matrix ([Supplementary Movie S1](#SD4){ref-type="supplementary-material"}). We have evaluated ([Fig. 3A, D](#f3){ref-type="fig"}) how J~m~ is altered after the immediate TBHP addition to ntgINS-1E cells pre-equilibrated with 25 m*M* glucose for 10 min (after 16-h preincubation with 3 m*M* glucose). In spite of the pro-oxidant nature of TBHP, J~m~ rates decreased to a minimum on TBHP addition ([Fig. 3A, D](#f3){ref-type="fig"}). Such attenuation of mitochondrial superoxide production ceased in the presence of [r]{.smallcaps}-BEL, but not [s]{.smallcaps}-BEL ([Fig. 3A, D](#f3){ref-type="fig"}), and was not observed in UCP2- ([Fig. 3B, C](#f3){ref-type="fig"}) and iPLA~2~γ-silenced INS-1E cells ([Fig. 3E, F](#f3){ref-type="fig"}).

![**Prevention of matrix-released superoxide after TBHP (A--F) or PA (G, H) addition is absent in UCP2- or iPLA~2~γ-silenced cells.** ntgINS-E cells of the corresponding scrambled sequences: *black symbols* or *bars*; UCP2-silenced cells: *dark red symbols* or *bars*; iPLA~2~γ-silenced cells: *green symbols* or *bars*. ANOVA (*n*=3--6): \**p*\<0.05; \*\**p*\<0.01; \*\*\**p*\<0.001. Rates of superoxide release into the mitochondrial matrix were assayed by confocal microscopy using MitoSOX *Red*. The magnitude of J~m~ in arbitrary units (a.u.) was determined as a slope of linearized fluorescence intensity traces *versus* time **(**exemplified in **A**, **B**, **D**, **E)**. Cells were preincubated with 3 m*M* glucose for 16 h and glucose was raised to 25 m*M* at the beginning, while the assay was conducted with no other agent (*triangles*) or as indicated with 25 μ*M* TBHP (*diamonds*), or with TBHP plus 5 μ*M* [r]{.smallcaps}-BEL (*squares*, " +[r]{.smallcaps}BEL"), or with TBHP plus 5 μ*M* [s]{.smallcaps}-BEL (*circles*, " +[s]{.smallcaps}BEL"). **(C, F)** Quantifications of J~m~ rates: The effects of [r]{.smallcaps}-BEL were quantified for J~m~ after TBHP induction of mitochondrial uncoupling ("TBHP") or without TBHP ("No add."). **(G, H)** Quantifications of J~m~ rates during β-oxidation of palmitate in INS-1E cells: The effects of [r]{.smallcaps}-BEL were quantified for J~m~ after PA induction of mitochondrial uncoupling ("PA"; 15 μ*M* PA) or without PA ("No add.").](fig-3){#f3}

We conclude that iPLA~2~γ and UCP2 synergy provides a suppression of mitochondrial superoxide production by mild uncoupling initiated by the TBHP-mediated activation of iPLA~2~γ. Consequently, we predict that in pancreatic β-cells the H~2~O~2~-activated iPLA~2~γ/UCP2 synergy provides an antioxidant mechanism, enabling a feedback downregulation of oxidative stress.

iPLA~2~γ activation during β-oxidation of palmitate in INS-1E cells {#s007}
-------------------------------------------------------------------

Mitochondrial iPLA~2~γ was also activated in ntgINS-1E cells by a matrix ROS/H~2~O~2~ burst, resulting from the ongoing β**-**oxidation of the added PA ([Fig. 2E](#f2){ref-type="fig"}). The electron-transfer flavoprotein:ubiquinone oxidoreductase forms superoxide during β**-**oxidation ([@B41], [@B46], [@B50]). Superoxide can be instantly transformed to H~2~O~2~ by SODs. We hypothesized that the resulting H~2~O~2~ directly activates iPLA~2~γ. Our results with the reconstituted recombinant iPLA~2~γ ([Fig. 2A--C](#f2){ref-type="fig"}) and experiments described next confirmed this hypothesis. Thus, PA addition induced respiratory elevation ([Fig. 4A, B](#f4){ref-type="fig"}) and ΔΨ~m~ decrease ([Fig. 4C, D](#f4){ref-type="fig"}), indicating mild mitochondrial uncoupling. Respiratory elevations, due to PA (Δ~PA~J~O2~), were more than two times higher in 25 m*M* glucose than in 3 m*M* glucose, and occurred even in the presence of [s]{.smallcaps}-BEL but not [r]{.smallcaps}-BEL ([Fig. 4A, B](#f4){ref-type="fig"}), indicating the iPLA~2~γ specificity. Importantly, the PA-induced uncoupling was virtually absent in cells silenced for either UCP2 ([Fig. 4A, C](#f4){ref-type="fig"}) or iPLA~2~γ ([Fig. 4B, D](#f4){ref-type="fig"}).

![**iPLA~2~γ activation during β-oxidation of palmitate in INS-1E cells.** Color coding as in [Figure 3](#f3){ref-type="fig"}. The effects of [r]{.smallcaps}-BEL and [s]{.smallcaps}-BEL were quantified for PA-induced acceleration of cell respiration, differences (Δ~PA~J~O2~) in respiration before and after the addition of 75 nmol PA·l0^−6^ cells **(A, B)** in the presence of 3 m*M* glucose ("Glc 3") and 25 m*M* glucose ("25"), and decreases (δ~PA~) in IMM potential ΔΨ~m~ in the presence of 25 m*M* glucose **(C, D)**. The ΔΨ~m~ decrease was assayed as a TMRE fluorescence increase (F~PA~--F~0~)/F~0~ from the initial (F~0~) to the elevated fluorescence after PA (F~PA~) in relative units. Uncoupling of mitochondria by 2.5 μ*M* FCCP prevented δ~PA~ΔΨ~m~ decreases, which then reached values \<0.5 (data not shown). Both [r]{.smallcaps}-BEL and [s]{.smallcaps}-BEL were 40 μ*M*. ANOVA (*n*=3--12): \**p*\<0.05; \*\**p*\<0.01; \*\*\**p*\<0.001. **(E**, **F)** The effects of palmitoyl-[dl]{.smallcaps}-carnitine **(E)** or [dl]{.smallcaps}-α-glycerolphosphate **(F).** The effects are shown **(E)** for 40 μ*M* [r]{.smallcaps}-BEL or 50 μ*M* etomoxir on respiratory responses to additions of 100 μ*M* palmitoyl-[dl]{.smallcaps}-carnitine administered with 2 μl of Lipofectamine 2000 (at 3 m*M* glucose); **(F)** for 11 m*M* dimethylsuccinate ("DMS") on respiratory responses to additions of 5 m*M* [dl]{.smallcaps}-α-glycerolphosphate at 3 m*M* glucose ("αGP") or 25 m*M* glucose ("αGP25"). ANOVA (*n*=3--12): \**p*\<0.05; \*\**p*\<0.01; ns, nonsignificant differences. **(G, H)** The effects of antioxidants on β-oxidation of palmitate in INS-1E cells: respiration assays at 25 m*M* glucose such as in *panel* **A (G)** or MitoSOX J~m~ assay **(H)** were conducted in the presence of antioxidants as indicated: 0.5 μ*M* SkQ1; 2 m*M N*-acetyl-[l]{.smallcaps}-cysteine; 7.5 μ*M* ebselen; 200 μ*M* Trolox; and 100 μ*M* MnTBAP. "Catalase" represents catalase overexpression. ANOVA (*n*=6): \**p*\<0.05; \*\**p*\<0.01; \*\*\**p*\<0.001.](fig-4){#f4}

Altogether, these data suggest that FAs instantly cleaved off phospholipids by iPLA~2~γ to determine the UCP2-mediated uncoupling, and that UCP2 requires such a specific nascent FA delivery (for UCP1 see Ref. [@B11]). This is because no response to PA addition took place in the presence of [r]{.smallcaps}-BEL (but not [s]{.smallcaps}-BEL) in ntgINS-1E cells. Analogously, a negligible response was also observed in iPLA~2~γ-silenced cells where UCP2 had to be intact. We have also demonstrated that PA can be substituted by palmitoyl-[dl]{.smallcaps}-carnitine administered to cells by Lipofectamine 2000 ([Fig. 4E](#f4){ref-type="fig"}) but not by [dl]{.smallcaps}-α-glycerolphosphate ([Fig. 4F](#f4){ref-type="fig"}). Both the β-oxidation inhibitor etomoxir and [r]{.smallcaps}-BEL inhibited palmitoyl-[dl]{.smallcaps}-carnitine-induced respiratory rise ([Fig. 4E](#f4){ref-type="fig"}). The [dl]{.smallcaps}-α-glycerolphosphate-driven respiration was higher in UCP2-silenced cells and was inhibited by a membrane-permeable succinate analog dimethylsuccinate ([Fig. 4F](#f4){ref-type="fig"}) but not by [r]{.smallcaps}-BEL (not shown).

A similar antioxidant effect in the mitochondrial matrix ([Fig. 3G, H](#f3){ref-type="fig"}) as seen with TBHP activation of iPLA~2~γ was found for iPLA~2~γ activation by H~2~O~2~, resulting from the pro-oxidant PA β-oxidation ([Fig. 5C](#f5){ref-type="fig"}). The superoxide release (J~m~) rates declined to a minimum on the PA addition ([Fig. 3G, H](#f3){ref-type="fig"}). Such attenuation of mitochondrial superoxide production ceased in the presence of [r]{.smallcaps}-BEL but not [s]{.smallcaps}-BEL ([Fig. 3G, H](#f3){ref-type="fig"}), and this was not observed in UCP2- ([Fig. 3G](#f3){ref-type="fig"}) and iPLA~2~γ-silenced cells ([Fig. 3H](#f3){ref-type="fig"}). We conclude that self-attenuation of oxidative stress at FA β-oxidation exists in INS-1E cells due to the UCP2/iPLA~2~γ synergy.

![**Cytosolic ROS and extracellular FA monitoring in INS-1E cells. (A--D)** Antioxidant effect of UCP2 and iPLA~2~γ synergy activated by β-oxidation of palmitate. For color coding, see [Figure 3](#f3){ref-type="fig"}. Rates of cytosolic oxidation J~c~ (ROS plus oxidized SH residues) were monitored by confocal microscopy using CellROX after additions of 15 μ*M* PA. The J~c~ rates were taken after 15 min **(A, B)** or during the first 5 min **(C, D)**. Both [r]{.smallcaps}-BEL and [s]{.smallcaps}-BEL were 50 μ*M*. ANOVA (*n*=6--9):\**p*\<0.05; \*\**p*\<0.01; \*\*\**p*\<0.001. **(E, F)** TBHP-induced free FA release was detected by confocal microscopy in the extracellular space based on quenching of ADIFAB2 fluorescence. Pericellular FA concentration values **(E)** were estimated from spectra **(**exemplified in **F)** obtained in the regions of interest selected around the outer perimeter of GFP-positive cells before and after the addition of glucose to the final 25 m*M* and 12.5 μ*M* TBHP, using a dissociation constant of 50 n*M*, which corresponds to an average value for plasma/serum FAs (cf. ADIFAB2 protocols, FFA Sciences, [www.ffasciences.com](www.ffasciences.com)). Where indicated, 200 n*M* SkQ1 was present ("SKQ"). GFP, green fluorescent protein; ROS, reactive oxygen species.](fig-5){#f5}

FA-induced uncoupling is prevented by antioxidants {#s008}
--------------------------------------------------

The PA-induced iPLA~2~γ/UCP2-dependent mitochondrial uncoupling in INS-1E cells at 25 m*M* glucose was prevented by the matrix-targeted antioxidant SkQ1, by ebselen but not by *N*-acetyl-[l]{.smallcaps}-cysteine ([Fig. 4G](#f4){ref-type="fig"}). Unlike with TBHP, it was also blocked by Trolox and MnTBAP ([Fig. 4G](#f4){ref-type="fig"}), reflecting superoxide and down-stream radical formation by β-oxidation. It was also blocked by catalase overexpression ([Fig. 4G](#f4){ref-type="fig"}), which abolished the resulting attenuation of superoxide formation ([Fig. 4H](#f4){ref-type="fig"}).

Concomitant redox changes in the cytosol of INS-1E cells {#s009}
--------------------------------------------------------

We have also studied redox changes in the cytosol of ntgINS-1E cells and confirmed that both PA β-oxidation ([Fig. 5A--D](#f5){ref-type="fig"}) and, as expected, TBHP additions (not shown) oxidize cytosol, when rates of oxidation (J~c~) were indicated by the cytosolic ROS fluorescent probe CellROX immediately after insults ([Fig. 5C, D](#f5){ref-type="fig"}). However, when detected ∼15 min after PA addition, the cytosolic oxidation rates J~c~ were faster in UCP2- ([Fig. 5A](#f5){ref-type="fig"}) and iPLA~2~γ-silenced cells ([Fig. 5B](#f5){ref-type="fig"}) when compared with ntgINS-1E cells. This difference ceased in the presence of [r]{.smallcaps}-BEL. We interpret that after the initial phase of β**-**oxidation, producing a substantial burst of superoxide converted thereafter to H~2~O~2~ penetrating to the cytosol ([Fig. 5C, D](#f5){ref-type="fig"}), the resulting iPLA~2~γ activation and the concomitant UCP2/iPLA~2~γ antioxidant synergy later gradually reverses the established pro-oxidant state of the cytosol. The overall ROS release rates to the cytosol are therefore attenuated ([Fig. 5A, B](#f5){ref-type="fig"}).

Mitochondrial iPLA~2~γ-cleaved free FAs are accessible for plasma membrane {#s010}
--------------------------------------------------------------------------

A confocal microscopy assay with the extracellular fluorescent free FA indicator ADIFAB2 demonstrated FA binding to the extracellular ADIFAB2, which ceased in iPLA~2~γ-silenced cells ([Fig. 5E, F](#f5){ref-type="fig"}). This demonstrates that FAs cleaved by iPLA~2~γ in mitochondria can be exported to bind to the extracellular ADIFAB2 and therefore are also accessible to the entire cell cytosol and plasma membrane.

Role of UCP2/iPLA~2~γ synergy in insulin release {#s011}
------------------------------------------------

Next, we set to analyze in detail the behavior of the glucose sensor. INS-1E cells with glucose lowered to 3 m*M* responded to the increasing glucose by elevating the respiration in a saturated manner till the final 25 m*M* glucose ([@B49]). ntgINS-1E cells responded in the same way ([Fig. 6A](#f6){ref-type="fig"}). With the UCP2 silencing, beginning at 9 m*M* glucose, this relationship was shifted to higher respiration increases ([Fig. 6A](#f6){ref-type="fig"}), indicating that mitochondria lacking UCP2 respond to a higher extent on GSIS. It is known that not only respiration but also ΔΨ~m~ increases after glucose addition ([@B49]), and this was observed in ntgINS-1E cells ([Fig. 6C](#f6){ref-type="fig"}). Again, these ΔΨ~m~ elevations at GSIS were higher in UCP2-silenced cells ([Fig. 6C](#f6){ref-type="fig"}). In contrast, both respiratory ([Fig. 6B](#f6){ref-type="fig"}) and ΔΨ~m~ responses ([Fig. 6D](#f6){ref-type="fig"}) to glucose in iPLA~2~γ-silenced cells were identical to their corresponding ntg controls. We conclude that UCP2 presence in ntgINS-1E cells diminishes respiratory and ΔΨ~m~ responses to the added glucose. These responses are intimately inherent to the glucose-sensing function of pancreatic β-cells. Hence, the UCP2 presence sacrifices a small portion of the glucose-sensing capacity (function range) for benefits of antioxidant protection. The simplest reasoning predicts that UCP2 does it *via* a mild uncoupling of mitochondria at state-3 (*i.e.,* at phosphorylating state). This is supported by the observed, slightly increased respiration on UCP2 silencing.

![**Changes after glucose addition to control, UCP2- or iPLA~2~γ-silenced cells.** For color and symbol coding, see [Figure 1](#f1){ref-type="fig"}. Cells were preincubated for 16 h in a cultivation medium with 3 m*M* glucose and assayed in it. Responses to the additional glucose with its indicated final concentration are shown for: **(A, B)** Respiratory elevations (*n*=9--25; *n*=110 for 25 m*M* glucose); ANOVA: \**p*\<0.05; \*\**p*\<0.01; \*\*\**p*\<0.001; **(C, D)** IMM potential increases Δ~Glc~ΔΨ~m~ (*n*=3), taken as TMRE fluorescence decreases (F~0~--F~Glucose~)/F~0~ from the initial (F~0~) to the decreased fluorescence after glucose (F~Glucose~) in relative units. Uncoupling of mitochondria by 2.5 μ*M* FCCP prevented δ~TBHP~ΔΨ~m~ increases, which then reached values \<0.1 (data not shown). ANOVA: \**p*\<0.05; **(E, F)** cytosolic ATP levels in the absence or presence of TBHP (250 μ*M*; *dashed bars*) assayed with no further addition ("Glc 3") or after glucose adjustment to 25 m*M* ("Glc 25"). ATP levels were quantified after 60 min. ANOVA (*n*=4--11): \*\**p*\<0.05.](fig-6){#f6}

However, the rates of glucose-stimulated insulin release in UCP2- or iPLA~2~γ-silenced INS-1E cells were equal to ntgINS-1E controls ([Fig. 7A](#f7){ref-type="fig"}). In the presence of TBHP addition, nonlinear (biphasic) insulin release was initially faster and attained higher magnitudes 10--60 min after glucose addition to UCP2- and iPLA~2~γ-silenced INS-1E cells ([Fig. 7B](#f7){ref-type="fig"}), demonstrating that unchanged and lower-magnitude insulin release rates in ntgINS-1E controls are depressed ([@B45]) in the presence of a pro-oxidant due to the iPLA~2~γ/UCP2-initiated uncoupling, similarly as previously observed ([@B48]). Hence, a portion of maximum possible insulin-secreting capacity is sacrificed for benefits of antioxidant protection. But independently of TBHP presence, ATP cell levels were equal 60 min after glucose addition, to all studied cells, to ntgINS-1E, UCP2- ([Fig. 6E](#f6){ref-type="fig"}) and iPLA~2~γ-silenced cells ([Fig. 6F](#f6){ref-type="fig"}). This implies that mild uncoupling is not able to substantially block OXPHOS, hence ATP synthesis in the long term. It should be noted, however, that TBHP alone accelerated insulin release in the absence of glucose, causing the redox-stimulated insulin secretion (RSIS) (cf. dashed fits in [Fig. 7B *vs.* 7A](#f7){ref-type="fig"}).

![**Glucose-stimulated insulin release in the absence or presence of pro-oxidant insult.** Changes in insulin release into Krebs-Ringer HEPES buffer were assayed: **(A)** in the absence or **(B**) presence of TBHP (25 μ*M*); or **(Ca, Cb, Cc)** 15 μ*M* and **(D)** 150 μ*M* PA, all added together with glucose, during 60 min after raising glucose to 25 m*M* or without glucose addition (*dashed fits* and *semi-filled symbols* or *gray circles* or *black circles* for ntg INS-1E cells). *Black symbols* or *fits*: ntg INS-1E cells; *dark red symbols* or *fits*: UCP2-silenced cells; *green symbols* or *fits*: iPLA~2~γ-silenced cells. **(Ca, Cb, Cc)** *Yellow-filled symbols* indicate data of GPR40-silenced cells; the *gray-filled symbols* represent measurements in the presence of GPR40 antagonist GW1100, added at the beginning. **(E, F)** Typical components extracted from **(B)** are shown in **(E)** and of **(A, C)** in **(F)**, for GPR40-relevant fatty acid-stimulated insulin secretion (FASIS *via* GRPR), redox-stimulated insulin secretion (RSIS) and GSIS. Before the experiment, cells were routinely cultivated with 11 m*M* glucose, transferred to the Krebs-Ringer HEPES buffer, and incubated in it for 10 min before glucose addition. Rates of insulin release were 3.7±0.2, 4.2±0.5, or 3.6±0.4 ng·min^−1^×10^−6^ cells in the absence of TBHP and 6.3±1.5, 9±3, or 12±5 ng·min^−1^×10^−6^ cells during first 20 min in the presence of TBHP in ntg controls, UCP2-silenced or iPLA~2~γ-silenced cells, respectively. **(C)** Rates of insulin release with 15 μ*M* PA were 16±2, 2.5±0.1, or 2.4±0.1 ng·min^−1^×10^−6^ cells in the absence of glucose and 22±8, 12±3, or 5.3±0.8 ng·min^−1^×10^−6^ cells during first 20 min with glucose in ntg controls, UCP2-silenced or iPLA~2~γ-silenced cells, respectively. GPR40, G-protein--coupled receptor 40; GSIS, glucose-stimulated insulin secretion.](fig-7){#f7}

Similar to TBHP, but to a much higher extent, externally added PA extremely elevated insulin release (also together with H~2~O~2~/ROS generated during its pro-oxidant β-oxidation). PA induced higher rates of insulin release and its nonlinear time course even in the absence of glucose in ntgINS-1E cells ([Fig. 7Ca](#f7){ref-type="fig"}, black dashed fit). This was not altered in cells with silenced phospholipase D ([Supplementary Fig. S4](#SD5){ref-type="supplementary-material"}). Surprisingly, in UCP2- and iPLA~2~γ-silenced INS-1E cells, PA promoted much less of the glucose-insensitive insulin release, regarding to an extent and also rates, for iPLA~2~γ-silenced cells ([Fig. 7Cb, Cc](#f7){ref-type="fig"}, dark red dashed or green dashed fit). At 15 μ*M* PA (∼4 pmol×10^−6^ cells), glucose only slightly further increased the already fast insulin release in ntgINS-1E and also the relatively slower insulin release in iPLA~2~γ-silenced cells ([Fig. 7Cb, Cc](#f7){ref-type="fig"} dark red or green fit). In UCP2-silenced cells, 15 μ*M* PA with glucose promoted an insulin release extent, attaining ∼50% of levels in ntgINS-1E cells after 60 min. It should be noted that at 15 μ*M* PA, the majority of PA is bound to the albumin present and partitioned into membranes, whereas only ∼1.3 n*M* PA was free in our experiment, representing a concentration comparable to normal plasma levels. The time course was similar to that with the TBPH pro-oxidant insult ([Fig. 7Cb *vs.* 7B](#f7){ref-type="fig"}). Similar results were obtained with 30 μ*M* PA (not shown). To simulate acute lipotoxicity, we used a much higher PA (150 μ*M*; exceeding 200 n*M* free PA). Here, the net GSIS was reduced down to 25% ([Fig. 7D](#f7){ref-type="fig"}), indicating such an acute lipotoxicity that overcomes the stimulating effect of PA. As a result, the insulin release in the absence of PA was equal to the one with PA in UCP2- and iPLA~2~γ-silenced cells.

Redox-activated iPLA~2~γ supplies FAs for GPR40-stimulated insulin release {#s012}
--------------------------------------------------------------------------

Surprisingly, the GPR40, previously indicated to act in insulin-stimulating responses ([@B11]), turned out to be a major player in excessive rates of PA--insulin release in ntgINS1-E cells ([Fig. 7Ca](#f7){ref-type="fig"}). This conclusion stems from the finding that in GPR40-silenced cells ([Fig. 7Ca](#f7){ref-type="fig"}, yellow symbols) and in ntgINS1-E cells subjected to the GPR40 antagonist GW1100 ([Fig. 7Ca](#f7){ref-type="fig"}, gray symbols) the PA-induced insulin release was profoundly inhibited to the levels induced by TBHP ([Fig. 7B](#f7){ref-type="fig"}) in both the absence and presence of glucose. In UCP2-silenced cells, where intermediate PA-induced insulin release rates *versus* ntg controls were assessed, GW1100 also slightly inhibited the PA-induced insulin release ([Fig. 7Cb](#f7){ref-type="fig"}). In contrast, in iPLA~2~γ-silenced INS-1E cells, GW1100 had no effect in the presence of glucose and its effect was very small in the absence of glucose ([Fig. 7Cc](#f7){ref-type="fig"}).

Taken together, we interpret these results as follows: In the situation where, promoted by sole FA β-oxidation, ROS activate insulin release in the absence (the net RSIS; [Fig. 7E, F](#f7){ref-type="fig"}) or presence of glucose (RSIS plus GSIS, [Fig. 7E, F](#f7){ref-type="fig"}), the lack of iPLA~2~γ evidently causes that no further FAs are cleaved, in contrast to the ongoing cleavage in ntg or UCP2-silenced cells. In ntg cells, it is not the added PA that stimulates GPR40, but FAs cleaved off phospholipids by iPLA~2~γ. Lysophosphatidic acid is excluded from GPR40 stimulation and subsequent insulin secretion, since silencing of phospholipase D did not change the observed fatty acid--stimulated insulin secretion (FASIS; [Supplementary Fig. S4](#SD5){ref-type="supplementary-material"}).

Discussion {#s013}
==========

Chronic lipotoxicity is a situation of persistent oxidative stress in pancreatic β-cells originating from the long-term intake of excessive FAs and lipid peroxidation products, which leads to GSIS impairment ([@B15], [@B19]). At low doses, FAs, however, stimulate insulin release ([Fig. 7C](#f7){ref-type="fig"}) ([@B15]). Studying immortalized but noncancer pancreatic β-cells, INS-1E cells ([@B37]), we demonstrated that a mild acute oxidative stress originates from the β-oxidation of FAs. This elevates superoxide in the mitochondrial matrix as well as H~2~O~2~ in the cytosol and simultaneously initiates a feedback downregulating mechanism that is capable of counteracting such a repeatable ROS burst given by postprandial physiological acute FA intake. Moreover, a different spectrum of FAs cleaved off mitochondrial phospholipids by iPLA~2~γ can spread within the cell serving as another messenger (as revealed by the ADIFAB2 assay, [Fig. 5E, F](#f5){ref-type="fig"}).

The antioxidant mechanism is provided by a synergy between H~2~O~2~-activated mitochondrial iPLA~2~γ and UCP2. The latter provides mild uncoupling, which attenuates the otherwise excessive superoxide production, the one resulting from β**-**oxidation at an un-attenuated state. The iPLA~2~γ/UCP2 antioxidant synergy is suited to provide a feedback downregulation of oxidative stress. It may counteract any pro-oxidant insult and shift of redox balance in the cell that comes over a certain threshold, that is, leading to H~2~O~2~ elevation sufficient for iPLA~2~γ activation. Our model ([Fig. 8A](#f8){ref-type="fig"}) is based on the finding that iPLA~2~γ is directly and reversibly activated by H~2~O~2~ (*ex vivo* by TBHP). Consequently, on H~2~O~2~ burst, iPLA~2~γ (or another isoform, if activated, but apparently not iPLA~2~β) ensures an antioxidant function in concert with UCP2, which then attenuates mitochondrial superoxide formation by mild uncoupling ([@B4], [@B18], [@B36]) ([Fig. 3](#f3){ref-type="fig"}). The consequent lowering of the inevitable H~2~O~2~ flow from mitochondria to the cell cytosol allows the suddenly released "spare" cytosolic antioxidant capacity to better cope with oxidative stress in the cell cytosol ([@B24]). This is the key principle behind how antioxidant protection from IMM is spread toward the cell ([@B24]).

![**Involvement of mitochondrial iPLA~2~γ in antioxidant protection and amplification of FA-induced insulin release. (A)** Antioxidant mechanism based on UCP2 and iPLA~2~γ synergy that is also protective against lipotoxicity in pancreatic β-cells. Acute lipotoxicity leads to FA β-oxidation in mitochondria. Not only the higher substrate load for the respiratory chain (Complexes I, III, IV) contributes to higher superoxide release, but also the electron-transferring flavoprotein:ubiquinone oxido-reductase produces superoxide on β**-**oxidation ([@B42]). Superoxide can be transformed to H~2~O~2~ by superoxide dismutases, SOD2/MnSOD in the matrix, or SOD1/CuZnSOD in the mitochondrial intermembrane space and in the cytosol. Subsequently, H~2~O~2~ activates iPLA~2~γ, which cleaves both saturated and unsaturated FAs off IMM phospholipids. Only these nascent FAs induce UCP2-mediated mild uncoupling, which inherently suppresses respiratory chain superoxide formation. Thus, iPLA~2~γ can be also activated by external oxidative stress as well as by redox signaling pathways, elevating H~2~O~2~ levels in its vicinity. Ca~L~, L-type Ca^2+^ channel; K~ATP~, ATP--sensitive K^+^ channel; O~2~^•−^, superoxide; Rcarn, acylcarnitine; RCoA, acyl-CoA. **(B)** Involvement of iPLA~2~γ in amplification of FA-induced GPR40 pathway of insulin secretion. After activation of iPLA~2~γ by H~2~O~2~ generated due to β-oxidation of incoming palmitic acid, FAs released from mitochondrial membranes provide feedback amplification of GPR40 response, leading to insulin surplus secretion. Lysophospholipids may also be cleaved by specific mitochondrial phospholipase D (mtPLD) ([@B14]). Phosphatidic acid (PhosA) released from normal phospholipids by mtPLD might be further processed by phosphatidic acid preferring PLA1 (PAPLA1). All mentioned lipid metabolites are involved in the glycerol lipid/FA cycle signaling stimulating insulin secretion ([@B44]).](fig-8){#f8}

The substantial extent of respiration and insulin release ([@B48], [@B54]) are sacrificed and utilized for such antioxidant function. The respiration extent of the β-cell glucose sensor corresponds to ∼30% of state-3 respiration ([Fig. 6A](#f6){ref-type="fig"}), whereas ∼15% is sacrificed for antioxidant mild uncoupling ([Fig. 6A](#f6){ref-type="fig"}, differences between ntg and UCP2--silenced cells). Hence, till 50% of maximum sensor capacity is utilized for the antioxidant role. Deriving from elevations of insulin secreted after 40--60 min with TBHP in UCP2-silenced *versus* ntg cells ([Fig. 7A, B](#f7){ref-type="fig"}), till 50% insulin surplus released in the absence of the antioxidant mechanism is also sacrificed for antioxidant protection. Nevertheless, the pro-oxidant impulse enhances insulin release rates in the absence of glucose ([Fig. 7B, C](#f7){ref-type="fig"}) ([@B31], [@B42]). Details of insulin release at the glucose or FA intake should be further studied within the more complex system of the Langerhans islets possessing numerous autocrine and paracrine interrelationships. They evoke certain limitations of our *in vitro* system used.

Rather complex results were obtained for FASIS or FASIS combined with GSIS ([Fig. 7Ca, E, F](#f7){ref-type="fig"}). At low (15 μ*M*, corresponding to 1.3 n*M* free) PA, the overall FASIS+GSIS is lower in UCP2- and iPLA~2~γ-silenced cells *versus* ntg cells, in spite of the tighter mitochondrial coupling *versus* ntg cells. The two components are involved in FASIS. The first one stems from the insulin release activated *via* the GPR40 pathway ([@B11]) ([Fig. 7C](#f7){ref-type="fig"}). The second one represents the net RSIS and is solely manifested in iPLA~2~γ-silenced cells without glucose. The GPR40 pathway of insulin secretion can be activated and is strongly amplified ([Fig. 8B](#f8){ref-type="fig"}) by FAs cleaved off phospholipids by iPLA~2~γ. Lysophospholipids remaining after the iPLA~2~γ reaction could be hypothetically cleaved by specific mitochondrial phospholipase D (mtPLD) ([@B14]), but as demonstrated this does not affect FASIS ([Supplementary Fig. S4](#SD5){ref-type="supplementary-material"}). FAs are involved in the glycerol lipid/FA cycle signaling stimulating insulin secretion ([@B44]).

The iPLA~2~γ is most likely initially activated *in vivo* by the pro-oxidant β-oxidation of FAs incoming from the blood. During FA β-oxidation, activation of iPLA~2~γ by H~2~O~2~ burst arises from the electron-transfer flavoprotein:ubiquinone oxidoreductase ([@B41], [@B46], [@B50]) and SODs activities. The situation resembles a self-accelerating cycle, since more active iPLA~2~γ provides more FAs for further β-oxidation, which further elevates ROS/H~2~O~2~. Besides iPLA~2~γ, these surplus ROS/H~2~O~2~ themselves trigger insulin secretion and, in parallel, persistently cleaved FAs promote GPR40 activation. All these contributors add on the resulting overstimulation of insulin secretion ([Fig. 7Ca](#f7){ref-type="fig"}), which is permanent (unlike with a single bolus of TBHP) until the added PA is metabolized. In its intermediate state, certain overstimulation is also possible with ablated UCP2 but logically not with ablated iPLA~2~γ. We estimated that at 15 μ*M* PA plus glucose, the insulin release induced during 60 min consists of ∼30% net GSIS, \<10% net RSIS, and 60% GPR40 pathway ([Fig. 7F](#f7){ref-type="fig"}). The activation of the GPR40 pathway vanished with ablated iPLA~2~γ. Without UCP2, hence at a more coupled state without antioxidant protection, the net GSIS increases to \>50% and RSIS is doubled ([Fig. 7F](#f7){ref-type="fig"}). Similar 50% net GSIS existed with TBHP ([Fig. 7E](#f7){ref-type="fig"}), inducing the net RSIS in the absence of glucose.

We also conclude that UCP2-mediated mild uncoupling is initiated only when free FAs are directly cleaved off the phospholipids at the UCP2 vicinity ([@B7]) by iPLA~2~γ (for UCP1 see Ref. [@B12]). In other words, only the nascent FAs are capable of initiating UCP2-mediated uncoupling and a simple PA addition to cells is insufficient ([Fig. 4B](#f4){ref-type="fig"}). FAs are considered the UCP2 cycling/wobbling substrates/cofactors, respectively, essential for their uncoupling function ([@B6], [@B7], [@B12], [@B18], [@B20], [@B53]).

Demonstrating UCP2/iPLA~2~γ antioxidant synergy and initiation of UCP2-mediated mild uncoupling by a nascent FA, we have resolved some contradictions that have been reported during the past decade for UCP2 role in pancreatic β-cells. Various reports of ROS-activated UCP2 function ([@B1], [@B28]) can be alternatively explained by the ROS-initiated iPLA~2~γ activation providing FAs for UCP2. Previously, a mild uncoupling in mitochondria isolated from INS-1E cells was also linked to UCP2, while accounting for approximately 30% of H^+^ leak ([@B1], [@B2]). Unlike negative demonstrations ([@B13]), we now show that UCP2 is activated exclusively by nascent FAs. This ensures that the net glucose sensing in pancreatic β-cells is not substantially affected by mild uncoupling, unless acute lipotoxicity and/or excessive oxidative stress activate the nascent FA delivery toward UCP2 by iPLA~2~γ. One would predict that the lack of either UCP2 or iPLA~2~γ must result in an easier reach of the oxidative stress threshold from which a pathological outcome is initiated. These characteristics were reported for UCP2 ablation ([@B29], [@B42], [@B48]).

The unique feature of the iPLA~2~γ protective role is represented by the fact that iPLA~2~γ is not constitutively active. Hence, without redox signaling or excessive oxidative stress (such as resulting in acute lipotoxicity), iPLA~2~γ does not contribute to mitochondrial uncoupling and to the diminished insulin release ([Fig. 7A, B](#f7){ref-type="fig"}). In turn, when activated, its synergy with UCP2 leads to the antioxidant protection at the expense of insulin release. Unless redox activated, no other mitochondria-localized PLA~2~ isoform can substitute iPLA~2~γ in these roles ([@B21], [@B25]). We excluded redox activation of iPLA~2~β, previously found in β-cell mitochondria ([@B34]).

In conclusion, our results elucidated iPLA~2~γ- plus UCP2-dependent regulation of mitochondrial superoxide production and insulin release in pancreatic β-cells. We describe a mechanism of free nascent FA-mediated antioxidant function, due to the synergic action of iPLA~2~γ and UCP2, counteracting mild sub-threshold lipotoxicity in pancreatic β-cells. The iPLA~2~γ-cleaved FAs may also participate in the lipid-mediated signaling such as in amplification of FA-induced insulin release *via* the GPR40 pathway.

The revealed redox activation of iPLA~2~γ and the requirement of nascent FAs for UCP2-mediated uncoupling ensure that the glucose sensing in pancreatic β-cells is not substantially affected by mild uncoupling, unless acute lipotoxicity and/or excessive oxidative stress activate the iPLA~2~γ/UCP2 antioxidant synergy. This synergy developed as an inherent antioxidant, cytoprotective, and specifically anti-lipotoxic mechanism that is protective before reaching a critical threshold and provides defense against long-term dysbalanced conditions, such as lipotoxicity. When these pro-oxidant impulses (stimulating otherwise antioxidant protection) are compromised, the inevitable self-accelerating vicious cycle leads to permanent oxidative stress, cell dysbalance, and the progression of type-2 diabetes pathology ([@B15], [@B23]). This progression has to be further elucidated and extended to future translational research.

Materials and Methods {#s014}
=====================

Chemicals {#s015}
---------

[r]{.smallcaps}-BEL, [s]{.smallcaps}-BEL, and Trolox were purchased from Cayman (Ann Arbor, MI); MnTBAP was from Merck Millipore (Billerica, MA). All other reagents were from Sigma (St. Louis, MO).

Cell cultivation {#s016}
----------------

Rat insulinoma INS-1E cells were a kind gift from Prof. Maechler, University of Geneva ([@B37]). Cells were cultivated with 11 m*M* glucose in RPMI 1640 medium with 2 m*M* [l]{.smallcaps}-glutamine, 10 m*M* HEPES, 2 g·l^−1^ sodium bicarbonate, 1 m*M* sodium pyruvate, 5% (v/v) fetal calf serum, 50 μ*M* mercaptoethanol, 50 IU·ml^−1^ penicillin, and 50 μg·ml^−1^ streptomycin ([@B49]). Cells were preincubated for 16 h in cultivation medium containing 3 m*M* glucose. The desired final glucose concentration was adjusted just immediately before each measurement.

Cell transfections and silencing {#s017}
--------------------------------

A BLOCK-iT Pol II miR RNAi system (Life Technologies, Carlsbad, CA) has been employed to express miRNAs against UCP2. The two miRNA sequences, 5′-TACAGA GTCGTAGAGGCCAATGTTTTGGCCACTGACTGACAT TGGCCTACGACTCTGTA-3′ and 5′-ATTTCGGGCAAC ATTGGGAGAGTTTTGGCCACTGACTGACTCTCCCAA TTGCCCGAAAT-3′, were designed using the BLOCK-iT RNAi Designer and annealed into double-strand oligonucleotides, which were inserted into the linearized miRNA expression vector pcDNA6.2-GW/EmGFP-miR. Individual miRNAs were chained up into tandem constructs. The vector with UCP2-miRNA or control miRNA plasmids was cloned by Gateway BP/LR reaction into pLenti6.2/V5-DEST expression vector, and final constructs were validated by DNA sequence analysis. Lentiviral expression plasmids were co-transfected with the ViraPower™ Packaging Mix (Life Technologies) into the 293LTV cells using Lipofectamine 2000 (Life Technologies). The lentiviral stock was used to transduce INS-1E cells, followed by selection of a stably transduced cell line by blasticidin and verification by a green fluorescent protein (GFP) inherent cytosolic reporter.

For catalase overexpression ([@B17]), pZeoSV2(+) vector bearing human catalase sequence (gift from C. Glorieux and Prof. J. Verrax, Université Catholique de Louvain, Belgium) was transiently transfected into INS-1E cells using Lipofectamine 2000 (2.5 ml·mg^−1^ DNA).

To silence iPLA~2~γ or iPLA~2~β, pGFP-V-RS vectors (Origene, Rockville, MD) as specific expression cassettes were used with inserted 29-mer shRNAs, 5′-CAAACACTGGC ACTCTTCAAGCAACCATGTCAAGAGCATGGTTGCT TGAAGAGTGCCAGTGTTTG-3′ or 5′-CAGTAGTGTCA CCAACTTGTTCTCAAACCTCAAGAGGGTTTGAGAAC AAGTTGGTGACACTACTG-3′, respectively. The same vectors with inserted scrambled shRNA expression cassettes served as negative controls. INS-1E cells were transiently transfected using Lipofectamine 2000 (2.5 ml·mg^−1^ DNA) and verified by the GFP cytosolic reporter. For GPR40 (FFAR1) or phospholipase PLD6 silencing, we used Silencer Select siRNAs (Life Technologies), cat. No. 4390771, IDs s141419 and s141420; or IDs s142381 and s142382. They were used in comparison *versus* negative control siRNA (cat. number 4390843). RNA oligonucleotides (20+20 pmol of siGPR40 *vs*. 40 pmol of negative control) were used.

High-resolution respirometry and fluorescent assays for ΔΨ~m~ and ATP monitoring {#s018}
--------------------------------------------------------------------------------

Cells were trypsinized, counted by a Countess Automated Cell Counter (Life Technologies), and adjusted to 2×10^6^ cells/ml. Respiration was detected by an Oxygraph 2k (cells at 37°C, isolated mitochondria at 30°C; Oroboros, Innsbruck, Austria). Rates taken 3 min after sequential additions of glucose, TBHP, or PA (when applied) were corrected for KCN-insensitive respiration. Five micromolars of tetramethylrhodamine ethyl ester (TMRE; Life Technologies) added immediately before the assay were used for ΔΨ~m~ monitoring on an RF 5301 PC spectrofluorometer (Shimadzu, Tokyo, Japan) in a stirred 2 ml cuvette with excitation at 561 nm (3 nm slit) and emission at 579 nm (5 nm slit). Trifluoromethoxy carbonylcyanide phenylhydrazone (FCCP) was titrated to a maximum (respiration) or added twice (ΔΨ~m~). ATP quantification was performed using ATP Assay bioluminescence kit HSII (Roche, Basel, Switzerland) and the spectrofluorometer at 557 nm (5 nm slit).

Confocal microscopy {#s019}
-------------------

A confocal inverted fluorescent microscope Leica TCS SP2 AOBS was employed, with a PL APO 100×/1.40--0.70 oil immersion objective (pinhole 1 Airy unit) and a sample chamber set to 37°C supplied with 5% CO~2~. Cells were seeded on poly-[l]{.smallcaps}-lysine-coated 22 mm glass coverslips (Marienfeld, Lauda-Königshofen, Germany) at 0.25×10^6^ cells/coverslip 2 days before the experiment or at 0.4×10^6^ cells/coverslip 1 day before the transient transfection and 3 days before the experiment.

Confocal microscopy monitoring of cytosolic ROS and extracellular FAs {#s020}
---------------------------------------------------------------------

Cytosolic ROS monitoring was ensured by 10 μ*M* CellROX (Life Technologies) after 30 min loading, while excited at 633 nm with a 1.2 mW HeNe laser and collecting emission between 650 and 700 nm. An ADIFAB2 FA indicator (FFA Sciences, San Diego, CA) was used to monitor extracellular free FAs, while excited with a 405 nm diode laser and collecting emission between 430 and 645 nm.

Confocal microscopy monitoring of superoxide released into mitochondrial matrix {#s021}
-------------------------------------------------------------------------------

A triphenylphosphonium-conjugated dihydroethidine, MitoSOX Red (Life Technologies), was used to monitor rates (J~m~) of *in situ* surplus superoxide release into the mitochondrial matrix ([@B10]). The surplus represents the portion of superoxide not neutralized by the matrix Mn-SOD. Using rates, any variations in initial background fluorescence are eliminated and the method is feasible for semiquantification of matrix-released superoxide even at low or collapsed ΔΨ~m~ ([@B10]). Excitation was at 488 nm by a 20 mW Argon laser, with emission collected between 550 and 650 nm, while the GFP reporter was checked between 508 and 516 nm. Cells were loaded with 4 μ*M* MitoSOX for 15 min. A series of confocal images were taken every 30 s for 20 min ([Supplementary Movie S1](#SD4){ref-type="supplementary-material"}). Regions of interest corresponding to mitochondria were selected using the Ellipse software (ViDiTo, Košice, Slovakia). Changes of integrated fluorescence intensity were quantified from plots of fluorescence in the selected areas *versus* time.

Assay for insulin release {#s022}
-------------------------

Cells were seeded at 0.4×10^6^ cells/well in poly-[l]{.smallcaps}-lysine-coated 12-well plates 1 day before the transient transfection and 3 days before the experiment. Insulin release was assayed using Rat Insulin ELISA kit (U-E type; Shibayagi, Shibukawa, Japan) in Krebs-Ringer HEPES buffer containing 2 m*M* glutamine and 0.1% bovine serum albumin after 10 min of preincubation before glucose addition.

SDS-PAGE and Western blotting {#s023}
-----------------------------

Silencing was verified by SDS-PAGE followed by Western blotting on mitochondria isolated from cells and using primary antibodies against UCP2 (No. 662047; Merck Millipore) or in cell lysates for iPLA~2~γ (PNPLA8 N-terminal., AP4706a; Abgent, San Diego, CA); otherwise, ATP-synthase β-subunit (ATPB, ab14730; Abcam, Cambridge, MA), TIM23 (611222; BD Biosciences, Franklin Lakes, NJ), β-actin (ab3280; Abcam), and horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit secondary antibody, respectively (Sigma) were used. Blots were visualized using an LAS-1000 Imager, and quantitative image analysis was performed with ImageJ software.

iPLA~2~γ reconstitution {#s024}
-----------------------

The recombinant human iPLA~2~γ was reconstituted into liposomes by adopting published protocols ([@B20]). The enzyme was purchased (PNPLA8; Novus Biologicals, Littleton, CO) or was cell expressed from a vector encoding His-tagged enzyme (GeneCopoeia, Rockville, MD) and affinity purified using a nickel resin column (Qiagen, Germantown, MD). Ten microgram per milliliter of Novus protein was dissolved in 1% *n*-lauroylsarcosine, passed through a Sephadex G-25-300 column, and equilibrated with an assay medium plus 0.1% *n*-octylpentaoxyethyelene (Bachem, Bubendorf, Switzerland). One hundred microgram per milliliter of the affinity-purified protein had to be treated with 10 m*M* DTT and dialyzed against the assay medium, in order to reversibly modify the protein to its reduced form. A Sephadex G-25-300 column (0.5% n-octylpentaoxyethyelene) was used to remove DTT. Aliquots in μg·(mg lipid)^−1^ (0.04 Novus protein; 0.4--0.8 affinity-purified protein) were mixed with phospholipids (Escherichia *coli* total lipid extract supplemented with 20% bovine heart cardiolipin; Avanti Polar Lipids, Alabaster, AL), to yield 28% cardiolipin, 46% phosphatidylethanolamine, 12% phosphatidylglycerol plus 14% other lipid, and 1 mg·(mg lipid)^−1^ *n*-octylpentaoxyethyelene. Proteoliposomes were formed by detergent removal using Bio-Beads SM-2 (Bio-Rad, Hercules, CA). Both the intraliposomal and assay medium contained Na^+^ salts of TES (50 m*M*), SO~4~^2−^ (80 m*M*), and EDTA (2 m*M*), pH 7.5. Sulfopropylquinolinium-based monitoring of FA release into the liposome interior or GC/MS analyses of cleaved FAs was performed.

Quantification of free FAs {#s025}
--------------------------

Free FAs released in liposomes or cells were quantified using GC/MS (6890 gas chromatograph, 5973 mass spectrometer; Agilent Technologies, Palo Alto, CA). Reaction mixtures were extracted with acidic 2-propanol/*n*-heptane, treated with ether/diazomethane at room temperature for 20 min, and evaporated under argon. The methylated FAs were reconstituted in 100 μl of *n*-heptane and analyzed by GC/MS. FAs were identified/quantified in comparison with spectra of purified standards. FA total content in phospholipids was evaluated after hydrolysis by 0.5 *M* NaOH at 60°C for 30 min, and after acidification and extraction.
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BSA

:   bovine serum albumin

Ca~L~

:   L-type Ca^2+^ channel

DTT

:   dithiothreitol

FA

:   fatty acid

FASIS

:   fatty acid-stimulated insulin secretion

FCCP

:   trifluoromethoxy carbonylcyanide phenylhydrazone

GC/MS

:   gas chromatography/mass spectrometry

GFP

:   green fluorescent protein

GPR40

:   G-protein--coupled receptor 40

GSIS

:   glucose-stimulated insulin secretion

IMM

:   inner mitochondrial membrane

K~ATP~

:   ATP-sensitive K^+^ channel

miRNA

:   microRNA

MnTBAP

:   Mn(III)tetrakis(4-benzoic acid)porphyrin

mtPLD

:   mitochondrial phospholipase D

ntg

:   nontargeting

OXPHOS

:   oxidative phosphorylation

PA

:   palmitic acid

PAPLA1

:   phosphatidic acid preferring PLA1

PNPLAs

:   patatin-like phospholipase domain-containing lipases

[r]{.smallcaps}-BEL

:   [r]{.smallcaps}-bromoenol lactone

Rcarn

:   acylcarnitine

RCoA

:   acyl-CoA

ROS

:   reactive oxygen species

RSIS

:   redox-stimulated insulin secretion

[s]{.smallcaps}-BEL

:   [s]{.smallcaps}-bromoenol lactone

SOD

:   superoxide dismutase

TBHP

:   *tert*-butylhydroperoxide

TMRE

:   tetramethylrhodamine ethyl ester

UCP

:   uncoupling protein
